This page contains brief information about idecabtagene vicleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Idecabtagene vicleucel is approved to treat:
- Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four previous treatments that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Idecabtagene vicleucel is only available as part of a special program called Abecma REMS (Risk Evaluation and Mitigation Strategies).
More About Idecabtagene Vicleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Idecabtagene Vicleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.